-
Alex Wong/Getty ImagesVirginia Gov. Abigail Spanberger will deliver Democrats' response on Tuesday following President Trump's State of the Union address. -
Matt Cardy/Getty ImagesFor decades, rising home prices have been an engine for middle-class wealth. Now a growing movement wants to slow — or even reverse — that trend. Are the politics around new housing development inherently stacked against them?
-
Russia launched its full-scale invasion of Ukraine four years ago, and the fighting continues. Here's a look at where the war stands today. -
The woman has no criminal record and is unsure what prompted the threat of removal. She fears being deported to Iran given her father's military service and her Christian faith. -
The prime-time address is a chance for the president to tout his record ahead of this year's midterm elections. But it comes at a moment when Trump has seen his agenda complicated on multiple fronts. -
For 50 years, a San Francisco-based group has created a space where fearful flyers can get supported exposure to air travel.
What does the Democratic leader see for himself in the years to come?
Department of Justice and Getty Images/Collage by Danielle A. Scruggs/NPR
-
FBI director invites fresh scrutiny over travels with appearance at US men's hockey team celebrationWhen the American men's hockey team retreated to their locker room to celebrate their Winter Olympics gold medal win, they were joined by a special guest from the United States: FBI Director Kash Patel. -
France's spat with the U.S. ambassador to Paris has taken another turn with the French foreign minister now saying the top U.S. diplomat in France must explain himself after ignoring a French summons. -
The Texas Republican is facing calls from fellow House Republicans to resign, following allegations of an affair with a staffer who later died by suicide. -
Photos of cities in Connecticut, New York, New Jersey and Massachusetts as they cope with a powerful winter storm. -
The Food and Drug Administration aims to evaluate treatments for rare diseases based on plausible evidence that they would work — without requiring a clinical trial first.
